Last Price
0.403
Today's Change
-0.013 (3.12%)
Day's Change
0.39 - 0.43
Trading Volume
1,194,244
Market Cap
9 Million
Shares Outstanding
23 Million
Avg Volume
13,071,578
Avg Price (50 Days)
0.34
Avg Price (200 Days)
0.39
PE Ratio
-1.09
EPS
-0.37
Earnings Announcement
29-Aug-2024
Previous Close
0.42
Open
0.42
Day's Range
0.3901 - 0.43
Year Range
0.19 - 1.58
Trading Volume
1,194,253
1 Day Change
-3.20%
5 Day Change
-29.63%
1 Month Change
81.35%
3 Month Change
8.81%
6 Month Change
18.41%
Ytd Change
-10.53%
1 Year Change
-57.62%
3 Year Change
-95.48%
5 Year Change
-85.62%
10 Year Change
-96.93%
Max Change
-99.24%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.